Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 10/20 | 0.82 |
| ▸ | MEN1 | O00255 | 4/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 4/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.82 |
| ▸ | NPC1 | O15118 | 2/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.82 |
| ▸ | MTOR | P42345 | 2/20 | 0.82 |
| ▸ | RAB9A | P51151 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | HTR2C | P28335 | 2/20 | 0.82 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.82 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.82 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoxetine SCHEMBL27334900 | 1.00 | SLC6A4 (0.82) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL6005182 | 1.00 | SLC6A4 (0.82) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL27524087 | 0.99 | SLC6A4 (0.80) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL5790618 | 0.99 | SLC6A4 (0.82) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8466282 | 0.92 | SLC6A4 (0.80) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL6008121 | 0.92 | SLC6A4 (0.88) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8722258 | 0.92 | SLC6A4 (0.88) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL3242735 | 0.91 | SLC6A4 (0.86) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL33947 | 0.91 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL570572 | 0.91 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1393724-B1 | Novel formulations for the transdermal administration of fluoxetine | ALZA CORP (US) | 2006-04-05 | — | — | EP | claimed |
| US-7011844-B2 | Formulations for the administration of fluoxetine | ALZA CORPORATION (US) | 2006-03-14 | — | — | US | claimed |
| US-20050186277-A1 | Novel formulations for the administration of fluoxetine | GALE ROBERT M (US) | 2005-08-25 | — | — | US | claimed |
| EP-0946184-B1 | NOVEL FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FLUOXETINE ACETATE AND FLUOXETINE MALEATE | ALZA CORP (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1393724-A2 | Novel formulations for the transdermal administration of fluoxetine | ALZA CORPORATION (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030166624-A1 | Novel formulations for the administration of fluoxetine | GALE ROBERT M (US) | 2003-09-04 | — | — | US | claimed |
| EP-0946184-A2 | NOVEL FORMULATIONS FOR THE ADMINISTRATION OF FLUOXETINE | ALZA CORPORATION (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998002169-A2 | NOVEL FORMULATIONS FOR THE ADMINISTRATION OF FLUOXETINE | ALZA CORPORATION (US) | 1998-01-22 | — | — | WO | claimed |
| CN-1042704-A | FLUOXETINE ANALOG | LILLY CO ELI (US) | 1990-06-06 | — | — | CN | claimed |
| CN-1794981-A | Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | FOREST LABORATORIES (US) | 2006-06-28 | — | — | CN | disclosed |
| EP-1393724-B1 | Novel formulations for the transdermal administration of fluoxetine | ALZA CORP (US) | 2006-04-05 | — | — | EP | disclosed |
| US-7011844-B2 | Formulations for the administration of fluoxetine | ALZA CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| US-20050186277-A1 | Novel formulations for the administration of fluoxetine | GALE ROBERT M (US) | 2005-08-25 | — | — | US | disclosed |
| EP-0946184-B1 | NOVEL FORMULATIONS FOR THE TRANSDERMAL ADMINISTRATION OF FLUOXETINE ACETATE AND FLUOXETINE MALEATE | ALZA CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030166624-A1 | Novel formulations for the administration of fluoxetine | GALE ROBERT M (US) | 2003-09-04 | — | — | US | disclosed |
| US-6512010-B1 | Devices for transdermally administering fluoxetine acetate to a subject through a body surface or membrane over a sustained time period | ALZA CORPORATION | 2003-01-28 | — | — | US | disclosed |
| US-6203817-B1 | TRANSDERMAL ADMINISTRATION OF A DRUG SALT OF A NON-ZWITTERIONIC DRUG IS DISCLOSED WHEREIN THE DRUG SALT COMPRISES A COMBINATION OF SURFACE ACTIVITY AND A LOW OCTANOL-WATER PARTITION COEFFICIENT; REDUCED SENSITIVITY | ALZA CORPORATION | 2001-03-20 | — | — | US | disclosed |
| EP-0946184-A2 | NOVEL FORMULATIONS FOR THE ADMINISTRATION OF FLUOXETINE | ALZA CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998002169-A2 | NOVEL FORMULATIONS FOR THE ADMINISTRATION OF FLUOXETINE | ALZA CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| CN-1042704-A | FLUOXETINE ANALOG | LILLY CO ELI (US) | 1990-06-06 | — | — | CN | disclosed |